Pharmaceutical Manufacturing Handbook: Production and

More documents

Recommendations

Info

1222 ORAL EXTENDED-RELEASE FORMULATIONS 142. Takka , S. , Rajbhandari , S. , and Sakr , A. ( 2001 ), Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets , Eur. J. Pharm. Biopharm. , 52 , 75 – 82 . 143. Nie , S. , Pan , W. , Li , X. , and Wu , X. ( 2004 ), The effect of citric acid added to hydroxypropyl methylcellulose (HPMC) matrix tablets on the release profi le of vinpocetine , Drug Dev. Ind. Pharm. , 30 , 627 – 635 . 144. Varma , M. V. S. , Kaushal , A. M. , and Garg , S. ( 2005 ), Infl uence of micro - environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices , J. Controlled Release , 103 , 499 – 510 . 145. Qiu , Y. , and Park , K. ( 2001 ), Environment - sensitive hydrogels for drug delivery , Adv. Drug Deliv. Rev. , 53 , 321 – 339 . 146. Bromberg , L. ( 2005 ), Intelligent hydrogels for the oral delivery of chemotherapeutics , Exp. Opin. Drug Deliv. , 2 , 1003 – 1013 . 147. Rowe , C. W. , Wang , C - C. , and Monkhouse , D. C. ( 2003 ), TheriForm technology , Drugs Pharm. Sci. , 126 , 77 – 87 . 148. Lee , K - J. , Kang , A. , Delfi no , J. J. , West , T. G. , Chetty , D. , Monkhouse , D. C. , and Yoo , J. ( 2003 ), Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form , Drug Dev. Ind. Pharm. , 29 , 967 – 979 . 149. Rocca , J. G. , and Park , K. ( 2004 ), Oral drug delivery: Prospects & challenges , Drug Deliv. Technol. , 4 , 52 – 54 , 57 .
SECTION 7 ROLE OF NANOTECHNOLOGY
Page 1:
PHARMACEUTICAL MANUFACTURING HANDBO
Page 5 and 6:
PHARMACEUTICAL MANUFACTURING HANDBO
Page 7 and 8:
CONTRIBUTORS Susanna Abrahms é n -
Page 9 and 10:
CONTRIBUTORS vii Eddy Castellanos G
Page 11 and 12:
CONTENTS PREFACE xiii SECTION 1 MAN
Page 13:
CONTENTS xi 5.11 Transdermal Drug D
Page 17:
SECTION 1 MANUFACTURING SPECIALTIES
Page 20 and 21:
4 BIOTECHNOLOGY-DERIVED DRUG PRODUC
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
10 BIOTECHNOLOGY-DERIVED DRUG PRODU
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
34 REGULATORY CONSIDERATIONS IN APP
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 75 and 76:
1.3 RADIOPHARMACEUTICAL MANUFACTURI
Page 77 and 78:
The terms tracer, radiotracer , and
Page 79 and 80:
number of atoms that disintegrate d
Page 81 and 82:
images that can also give quantitat
Page 83 and 84:
PRODUCT DEVELOPMENT 67 Product Stab
Page 85 and 86:
MANUFACTURING ASPECTS 69 stations s
Page 87 and 88:
In general, the manufacturing of mo
Page 89 and 90:
MANUFACTURING ASPECTS 73 Production
Page 91 and 92:
PRODUCT MANUFACTURING 75 tainer. Th
Page 93 and 94:
PRODUCT MANUFACTURING 77 practical
Page 95 and 96:
PRODUCT MANUFACTURING 79 these radi
Page 97 and 98:
PRODUCT MANUFACTURING 81 Most of th
Page 99 and 100:
PRODUCT MANUFACTURING 83 PET Radiop
Page 101 and 102:
PRODUCT MANUFACTURING 85 FIGURE 5 S
Page 103 and 104:
PRODUCT MANUFACTURING 87 tions in t
Page 105 and 106:
QUALITY CONSIDERATIONS 89 regulatio
Page 107 and 108:
L1 L2 TC-MDP + Hydr. Tc TC-MDP + Tc
Page 109 and 110:
EXTEMPORANEOUS PREPARATION OF RADIO
Page 111 and 112:
Independent of which regulation app
Page 113:
SECTION 2 ASEPTIC PROCESSING
Page 116 and 117:
100 STERILE PRODUCT MANUFACTURING 2
Page 118 and 119:
102 STERILE PRODUCT MANUFACTURING A
Page 120 and 121:
104 STERILE PRODUCT MANUFACTURING T
Page 122 and 123:
106 STERILE PRODUCT MANUFACTURING E
Page 124 and 125:
108 STERILE PRODUCT MANUFACTURING I
Page 126 and 127:
Page 128 and 129:
112 STERILE PRODUCT MANUFACTURING c
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
118 STERILE PRODUCT MANUFACTURING i
Page 136 and 137:
120 STERILE PRODUCT MANUFACTURING o
Page 138 and 139:
122 STERILE PRODUCT MANUFACTURING a
Page 140 and 141:
124 STERILE PRODUCT MANUFACTURING a
Page 142 and 143:
126 STERILE PRODUCT MANUFACTURING e
Page 144 and 145:
128 STERILE PRODUCT MANUFACTURING A
Page 146 and 147:
Page 148 and 149:
132 STERILE PRODUCT MANUFACTURING p
Page 150 and 151:
Page 153:
SECTION 3 FACILITY
Page 156 and 157:
140 EFFECT OF SCALE-UP ON OPERATION
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
160 PACKAGING AND LABELING 3.2.1 3.
Page 178 and 179:
162 PACKAGING AND LABELING signifi
Page 180 and 181:
164 PACKAGING AND LABELING Although
Page 182 and 183:
166 PACKAGING AND LABELING componen
Page 184 and 185:
168 PACKAGING AND LABELING sions. T
Page 186 and 187:
170 PACKAGING AND LABELING TABLE 1
Page 188 and 189:
172 PACKAGING AND LABELING the stab
Page 190 and 191:
174 PACKAGING AND LABELING and accu
Page 192 and 193:
176 PACKAGING AND LABELING The safe
Page 194 and 195:
178 PACKAGING AND LABELING If the p
Page 196 and 197:
180 PACKAGING AND LABELING exposure
Page 198 and 199:
182 PACKAGING AND LABELING In many
Page 200 and 201:
184 PACKAGING AND LABELING Nonpharm
Page 202 and 203:
186 PACKAGING AND LABELING In 1906,
Page 204 and 205:
188 PACKAGING AND LABELING A medica
Page 206 and 207:
190 PACKAGING AND LABELING The inst
Page 208 and 209:
192 PACKAGING AND LABELING the poun
Page 210 and 211:
194 PACKAGING AND LABELING • (4)
Page 212 and 213:
196 PACKAGING AND LABELING In the c
Page 214 and 215:
198 PACKAGING AND LABELING • Inte
Page 216 and 217:
200 PACKAGING AND LABELING 27. U.S.
Page 218 and 219:
202 CLEAN-FACILITY DESIGN, CONSTRUC
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 251 and 252:
4.1 SOLID DOSAGE FORMS Barbara R. C
Page 253 and 254:
TABLE 2 Types of Solid Dosage Form
Page 255 and 256:
(GI) tract or for systemic effects.
Page 257 and 258:
EXCIPIENTS IN SOLID DOSE FORMULATIO
Page 259 and 260:
EXCIPIENTS IN SOLID DOSE FORMULATIO
Page 261 and 262:
HARD AND SOFT GELATIN CAPSULES 245
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
participants from the FDA, industry
Page 269 and 270:
in the mouth. Compressed lozenges (
Page 271 and 272:
ittle fi lm, have no unpleasant tas
Page 273 and 274:
CHEWING GUMS 257 4.1.10.2 Manufactu
Page 275 and 276:
already dissolved in the saliva pri
Page 277 and 278:
ORALLY DISINTEGRATING TABLETS 261 a
Page 279 and 280:
tions. Some buccal formulations hav
Page 281:
REFERENCES 265 32. Habib , W. , Kha
Page 284 and 285:
268 SEMISOLID DOSAGES: OINTMENTS, C
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
314 LIQUID DOSAGE FORMS 4.3.1 INTRO
Page 332 and 333:
316 LIQUID DOSAGE FORMS 4.3.2 GENER
Page 334 and 335:
318 LIQUID DOSAGE FORMS design, bui
Page 336 and 337:
320 LIQUID DOSAGE FORMS tions with
Page 338 and 339:
322 LIQUID DOSAGE FORMS Dosing Pump
Page 340 and 341:
324 LIQUID DOSAGE FORMS However, th
Page 342 and 343:
326 LIQUID DOSAGE FORMS Location of
Page 344 and 345:
328 LIQUID DOSAGE FORMS Solid drugs
Page 346 and 347:
330 LIQUID DOSAGE FORMS TABLE 3 Emu
Page 348 and 349:
332 LIQUID DOSAGE FORMS Temperature
Page 350 and 351:
334 LIQUID DOSAGE FORMS for viscosi
Page 352 and 353:
336 LIQUID DOSAGE FORMS spectrum, s
Page 354 and 355:
338 LIQUID DOSAGE FORMS Product Spe
Page 356 and 357:
340 LIQUID DOSAGE FORMS Liquid, Ext
Page 358 and 359:
342 LIQUID DOSAGE FORMS 7. Kourouna
Page 360 and 361:
344 LIQUID DOSAGE FORMS 46. Miller
Page 363 and 364:
5.1 CONTROLLED - RELEASE DOSAGE FOR
Page 365 and 366:
CONTROLLED-RELEASE DRUG DELIVERY SY
Page 367 and 368:
CONTROLLED-RELEASE FORMULATIONS 351
Page 369 and 370:
dosage forms [12] . For example, or
Page 371 and 372:
Degradation Liver Hydrolytic Enzyma
Page 373 and 374:
CONTROLLED-RELEASE ORAL DOSAGE FORM
Page 375 and 376:
DESIGN AND FABRICATION OF CONTROLLE
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
TECHNOLOGIES FOR DEVELOPING TRANSDE
Page 385 and 386:
TECHNOLOGIES FOR DEVELOPING TRANSDE
Page 387 and 388:
RELEASE OF DRUGS FROM CONTROLLED-RE
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
REFERENCES 387 16. Anal , A. K. ( 2
Page 405 and 406:
REFERENCES 389 57. M ü ller , R. H
Page 407 and 408:
REFERENCES 391 96. Sungthongjeen ,
Page 409 and 410:
5.2 PROGRESS IN DESIGN OF BIODEGRAD
Page 411 and 412:
INTRODUCTION 395 sequences. In addi
Page 413 and 414:
TABLE 2 Injectable Peptide/Proteins
Page 415 and 416:
PEPTIDE/PROTEIN-LOADED MICROSPHERE
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
ANALYTICAL CHARACTERIZATION 405 imm
Page 423 and 424:
IMMUNE SYSTEM INTERACTION WITH INJE
Page 425 and 426:
INJECTABLE PEPTIDE/PROTEIN-LOADED M
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
PEPTIDE/PROTEIN ENCAPSULATED INTO B
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
REFERENCES 427 novel ways to reduce
Page 445 and 446:
REFERENCES 429 31. Morlock , M. , K
Page 447 and 448:
REFERENCES 431 63. Lam , X. M. , Du
Page 449 and 450:
REFERENCES 433 95. van de Weert , M
Page 451 and 452:
REFERENCES 435 130. Bilati , U. , A
Page 453 and 454:
REFERENCES 437 166. Means , G. E. ,
Page 455 and 456:
REFERENCES 439 bic poly(lactide -co
Page 457:
REFERENCES 441 237. Singh , M. , Li
Page 460 and 461:
444 LIPOSOMES AND DRUG DELIVERY (sm
Page 462 and 463:
446 LIPOSOMES AND DRUG DELIVERY Con
Page 464 and 465:
448 LIPOSOMES AND DRUG DELIVERY and
Page 466 and 467:
450 LIPOSOMES AND DRUG DELIVERY tec
Page 468 and 469:
452 LIPOSOMES AND DRUG DELIVERY 250
Page 470 and 471:
454 LIPOSOMES AND DRUG DELIVERY a s
Page 472 and 473:
456 LIPOSOMES AND DRUG DELIVERY For
Page 474 and 475:
458 LIPOSOMES AND DRUG DELIVERY con
Page 476 and 477:
460 LIPOSOMES AND DRUG DELIVERY The
Page 478 and 479:
462 LIPOSOMES AND DRUG DELIVERY in
Page 480 and 481:
464 LIPOSOMES AND DRUG DELIVERY c a
Page 482 and 483:
466 LIPOSOMES AND DRUG DELIVERY Eve
Page 484 and 485:
468 LIPOSOMES AND DRUG DELIVERY inc
Page 486 and 487:
470 LIPOSOMES AND DRUG DELIVERY wit
Page 488 and 489:
472 LIPOSOMES AND DRUG DELIVERY i.v
Page 490 and 491:
474 LIPOSOMES AND DRUG DELIVERY for
Page 492 and 493:
476 LIPOSOMES AND DRUG DELIVERY bet
Page 494 and 495:
478 LIPOSOMES AND DRUG DELIVERY cli
Page 496 and 497:
480 LIPOSOMES AND DRUG DELIVERY lea
Page 498 and 499:
482 LIPOSOMES AND DRUG DELIVERY Vag
Page 500 and 501:
484 LIPOSOMES AND DRUG DELIVERY TAB
Page 502 and 503:
486 LIPOSOMES AND DRUG DELIVERY thr
Page 504 and 505:
488 LIPOSOMES AND DRUG DELIVERY TAB
Page 506 and 507:
490 LIPOSOMES AND DRUG DELIVERY tar
Page 508 and 509:
492 LIPOSOMES AND DRUG DELIVERY tha
Page 510 and 511:
494 LIPOSOMES AND DRUG DELIVERY wit
Page 512 and 513:
496 LIPOSOMES AND DRUG DELIVERY Pul
Page 514 and 515:
498 LIPOSOMES AND DRUG DELIVERY whi
Page 516 and 517:
500 LIPOSOMES AND DRUG DELIVERY Inc
Page 518 and 519:
502 LIPOSOMES AND DRUG DELIVERY Per
Page 520 and 521:
504 LIPOSOMES AND DRUG DELIVERY can
Page 522 and 523:
506 LIPOSOMES AND DRUG DELIVERY Tum
Page 524 and 525:
508 LIPOSOMES AND DRUG DELIVERY 25.
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
Page 540 and 541:
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 548 and 549:
Page 551 and 552:
5.4 BIODEGRADABLE NANOPARTICLES Sud
Page 553 and 554:
NATURAL BIODEGRADABLE POLYMERIC NAN
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
and drug loading of gliadin nanopar
Page 561 and 562:
SYNTHETIC BIODEGRADABLE POLYMERIC N
Page 563 and 564:
APPLICATIONS OF BIODEGRADABLE NANOP
Page 565 and 566:
PHYSICOCHEMICAL CHARACTERIZATION OF
Page 567 and 568:
TARGETING NANOPARTICLES BY SURFACE
Page 569 and 570:
5.4.9 CONCLUSIONS Biodegradable nan
Page 571 and 572:
REFERENCES 555 of a model protein (
Page 573 and 574:
REFERENCES 557 65. Kaul , G. , and
Page 575 and 576:
REFERENCES 559 99. Carino , G. P. ,
Page 577 and 578:
REFERENCES 561 133. Na , K. , Lee ,
Page 579 and 580:
REFERENCES 563 168. Freitas , C. ,
Page 581 and 582:
5.5 RECOMBINANT SACCHAROMYCES CEREV
Page 583 and 584:
Potential Medical Applications of B
Page 585 and 586:
BIODRUG CONCEPT USING YEAST AS VECT
Page 587 and 588:
BIODRUG CONCEPT USING YEAST AS VECT
Page 589 and 590:
Cumulative ileal delivery of viable
Page 591 and 592:
tine [30] . No signal was detectabl
Page 593 and 594:
ORAL FORMULATION OF RECOMBINANT YEA
Page 595 and 596:
Cumulative ileal delivery of viable
Page 597 and 598:
ORAL FORMULATION OF RECOMBINANT YEA
Page 599 and 600:
Viable yeasts released (% of initia
Page 601 and 602:
Steidler et al. [47] have already d
Page 603 and 604:
REFERENCES 587 23. Steidler , L. (
Page 605 and 606:
REFERENCES 589 nant yeasts as novel
Page 607 and 608:
5.6 NASAL DELIVERY OF PEPTIDE AND N
Page 609 and 610:
fi rst - pass metabolism and gut -
Page 611 and 612:
[6] . The nasal blood vessels can b
Page 613 and 614:
FACTORS INFLUENCING NASAL DRUG ABSO
Page 615 and 616:
5.6.3.6 Type of Delivery Device FAC
Page 617 and 618:
FACTORS INFLUENCING NASAL DRUG ABSO
Page 619 and 620:
FIGURE 4 ( a ) Optinose multidose l
Page 621 and 622:
Dogs, sheep, and monkeys can be kep
Page 623 and 624:
NASAL DELIVERY OF PEPTIDE AND HIGH-
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
in solutions containing different c
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Morphine plasma concentration (nmol
Page 641 and 642:
Concentration (μg/L) 1000 100 10 1
Page 643 and 644:
NASAL DELIVERY OF NONPEPTIDE MOLECU
Page 645 and 646:
NASAL DELIVERY OF NONPEPTIDE MOLECU
Page 647 and 648:
OPTION FOR DELIVERY OF DRUGS TO CEN
Page 649 and 650:
pseudostratifi ed epithelium compri
Page 651 and 652:
NASAL DELIVERY OF VACCINES 635 Howe
Page 653 and 654:
TABLE 5 Continued Delivery System/A
Page 655 and 656:
REFERENCES 639 23. Hardy , J. G. ,
Page 657 and 658:
REFERENCES 641 60. Collens , W. S.
Page 659 and 660:
REFERENCES 643 97. Eden , S. ( 1979
Page 661 and 662:
REFERENCES 645 comparison with oral
Page 663 and 664:
REFERENCES 647 172. Sakane , T. , A
Page 665 and 666:
REFERENCES 649 213. McCluskie , M.
Page 667 and 668:
5.7 NASAL POWDER DRUG DELIVERY Jele
Page 669 and 670:
NASAL DRY POWDER FORMULATIONS 653 t
Page 671 and 672:
POLYMERS IN NASAL POWDER DELIVERY S
Page 673 and 674:
POLYMERS IN NASAL POWDER DELIVERY S
Page 675 and 676:
MICROSPHERES AS NASAL DRUG DELIVERY
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
TOXICOLOGICAL CONSIDERATIONS 667 et
Page 685 and 686:
Summary of Research Work on Nasal D
Page 687 and 688:
Powder Formulation Preparation Meth
Page 689 and 690:
Powder Formulation Preparation Meth
Page 691 and 692:
REFERENCES 675 19. Van der Lubben ,
Page 693 and 694:
REFERENCES 677 54. Witschi , C. , a
Page 695 and 696:
REFERENCES 679 91. Varshosaz , J. ,
Page 697:
REFERENCES 681 126. Jorissen , M. ,
Page 700 and 701:
684 AEROSOL DRUG DELIVERY 5.8.8 5.8
Page 702 and 703:
686 AEROSOL DRUG DELIVERY other sig
Page 704 and 705:
688 AEROSOL DRUG DELIVERY are a num
Page 706 and 707:
690 AEROSOL DRUG DELIVERY 5.8.5 MET
Page 708 and 709:
692 AEROSOL DRUG DELIVERY TABLE 1 S
Page 710 and 711:
694 AEROSOL DRUG DELIVERY valve siz
Page 712 and 713:
696 AEROSOL DRUG DELIVERY Ferrule U
Page 714 and 715:
698 AEROSOL DRUG DELIVERY 5.8.5.6 A
Page 716 and 717:
700 AEROSOL DRUG DELIVERY 5.8.5.10
Page 718 and 719:
702 AEROSOL DRUG DELIVERY low inter
Page 720 and 721:
704 AEROSOL DRUG DELIVERY Transpare
Page 722 and 723:
706 AEROSOL DRUG DELIVERY of the cl
Page 724 and 725:
708 AEROSOL DRUG DELIVERY is achiev
Page 726 and 727:
710 AEROSOL DRUG DELIVERY Aerosol g
Page 728 and 729:
712 AEROSOL DRUG DELIVERY REFERENCE
Page 730 and 731:
714 AEROSOL DRUG DELIVERY 42. Witek
Page 732 and 733:
716 AEROSOL DRUG DELIVERY 81. Ohmor
Page 734 and 735:
718 AEROSOL DRUG DELIVERY 119. Lewi
Page 736 and 737:
720 AEROSOL DRUG DELIVERY 153. Terz
Page 738 and 739:
722 AEROSOL DRUG DELIVERY 189. Sham
Page 740 and 741:
724 AEROSOL DRUG DELIVERY 225. Newh
Page 742 and 743:
726 AEROSOL DRUG DELIVERY 263. Dolo
Page 745 and 746:
5.9 OCULAR DRUG DELIVERY Ilva D. Ru
Page 747 and 748:
CHALLENGES IN OCULAR DRUG DELIVERY
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
FORMULATION APPROACHES TO IMPROVE O
Page 755 and 756:
Page 757 and 758:
Drug Fluorescein FORMULATION APPROA
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
is characterized by a transient ove
Page 771 and 772:
REFERENCES 755 11. Klyce , S. D. ,
Page 773 and 774:
REFERENCES 757 53. Saettone , M. F.
Page 775 and 776:
REFERENCES 759 87. Lin , H. R. , an
Page 777 and 778:
REFERENCES 761 122. Durrani , A. M.
Page 779 and 780:
REFERENCES 763 158. Weyenberg , W.
Page 781 and 782:
REFERENCES 765 of various ophthalmi
Page 783:
REFERENCES 767 233. Grass , G. M. ,
Page 786 and 787:
770 MICROEMULSIONS AS DRUG DELIVERY
Page 788 and 789:
Page 790 and 791:
Page 792 and 793:
Page 794 and 795:
Page 796 and 797:
Page 798 and 799:
Page 800 and 801:
Page 802 and 803:
Page 804 and 805:
Page 806 and 807:
Page 808 and 809:
Page 810 and 811:
794 TRANSDERMAL DRUG DELIVERY 5.11.
Page 812 and 813:
796 TRANSDERMAL DRUG DELIVERY conta
Page 814 and 815:
798 TRANSDERMAL DRUG DELIVERY 5.11.
Page 816 and 817:
800 TRANSDERMAL DRUG DELIVERY FIGUR
Page 818 and 819:
802 TRANSDERMAL DRUG DELIVERY a rat
Page 820 and 821:
804 TRANSDERMAL DRUG DELIVERY passi
Page 822 and 823:
806 TRANSDERMAL DRUG DELIVERY 19. E
Page 825 and 826:
5.12 VAGINAL DRUG DELIVERY Jos é d
Page 827 and 828:
Therefore, this chapter discusses t
Page 829 and 830:
THE HUMAN VAGINA 813 thetic innerva
Page 831 and 832:
THE HUMAN VAGINA 815 the upper repr
Page 833 and 834:
THE HUMAN VAGINA 817 tant in the re
Page 835 and 836:
GENERAL FEATURES OF VAGINAL DRUG DE
Page 837 and 838:
Although this strategy may enhance
Page 839 and 840:
VAGINAL DRUG DELIVERY SYSTEMS 823 a
Page 841 and 842:
VAGINAL DRUG DELIVERY SYSTEMS 825 f
Page 843 and 844:
VAGINAL DRUG DELIVERY SYSTEMS 827 f
Page 845 and 846:
Amount released, μg/day 800 700 60
Page 847 and 848:
VAGINAL DRUG DELIVERY SYSTEMS 831 5
Page 849 and 850:
TABLE 4 Examples of Mucoadhesive Po
Page 851 and 852:
VAGINAL DRUG DELIVERY SYSTEMS 835 i
Page 853 and 854:
PHARMACEUTICAL EVALUATION OF VAGINA
Page 855 and 856:
Page 857 and 858:
Page 859 and 860:
CLINICAL USAGE AND POTENTIAL OF VAG
Page 861 and 862:
Page 863 and 864:
Page 865 and 866:
Page 867 and 868:
Page 869 and 870:
TABLE 6 Selected Drugs Administered
Page 871 and 872:
Selected Veterinary Vaginal Drug De
Page 873 and 874:
REFERENCES 857 Much work remains to
Page 875 and 876:
REFERENCES 859 33. Hocini , H. , Ba
Page 877 and 878:
REFERENCES 861 70. Kristmundsdottir
Page 879 and 880:
REFERENCES 863 105. McClelland , R.
Page 881 and 882:
REFERENCES 865 141. Kuyoh , M. A. ,
Page 883 and 884:
REFERENCES 867 178. Ondracek , J. ,
Page 885 and 886:
REFERENCES 869 212. Bagga , R. , Ra
Page 887 and 888:
REFERENCES 871 244. International W
Page 889 and 890:
REFERENCES 873 276. Mor , E. , Saad
Page 891 and 892:
REFERENCES 875 310. Saltzman , W. M
Page 893 and 894:
REFERENCES 877 vaginal microbicides
Page 895:
SECTION 6 TABLET PRODUCTION
Page 898 and 899:
882 PHARMACEUTICAL PREFORMULATION 6
Page 900 and 901:
884 PHARMACEUTICAL PREFORMULATION E
Page 902 and 903:
886 PHARMACEUTICAL PREFORMULATION T
Page 904 and 905:
Page 906 and 907:
Page 908 and 909:
892 PHARMACEUTICAL PREFORMULATION p
Page 910 and 911:
Page 912 and 913:
Page 914 and 915:
898 PHARMACEUTICAL PREFORMULATION l
Page 916 and 917:
Page 918 and 919:
902 PHARMACEUTICAL PREFORMULATION s
Page 920 and 921:
904 PHARMACEUTICAL PREFORMULATION C
Page 922 and 923:
906 PHARMACEUTICAL PREFORMULATION p
Page 924 and 925:
Page 926 and 927:
Page 928 and 929:
912 PHARMACEUTICAL PREFORMULATION D
Page 930 and 931:
Page 932 and 933:
916 PHARMACEUTICAL PREFORMULATION u
Page 934 and 935:
918 PHARMACEUTICAL PREFORMULATION d
Page 936 and 937:
920 PHARMACEUTICAL PREFORMULATION q
Page 938 and 939:
922 PHARMACEUTICAL PREFORMULATION w
Page 940 and 941:
Page 942 and 943:
Page 944 and 945:
928 PHARMACEUTICAL PREFORMULATION a
Page 946 and 947:
930 PHARMACEUTICAL PREFORMULATION a
Page 949 and 950:
6.2 ROLE OF PREFORMULATION IN DEVEL
Page 951 and 952:
maceutics ” documentation forms a
Page 953 and 954:
e altered without any change in the
Page 955 and 956:
Solubility Heat flow II I T m,II Ts
Page 957 and 958:
TABLE 2 Techniques to Characterize
Page 959 and 960:
Percent weight loss Heat flow (a) (
Page 961 and 962:
Heat flow Intensity 100 50 Endother
Page 963 and 964:
Change in mass (%) PHYSICAL/BULK CH
Page 965 and 966:
6.2.2.6 Powder Flow and Compressibi
Page 967 and 968:
Solvent required for 1 gm of solid
Page 969 and 970:
⎧ 100 ⎪ Ka 1+10 Percent ionized
Page 971 and 972:
Percent Ionization Percent Ionizati
Page 973 and 974:
SOLUBILITY CHARACTERISTICS 957 para
Page 975 and 976:
SOLUBILITY CHARACTERISTICS 959 of p
Page 977 and 978:
Dissolution studies pH solubility p
Page 979 and 980:
High Permeability Low SOLUBILITY CH
Page 981 and 982:
is evident form the fact [51] that
Page 983 and 984:
independent of initial drug concent
Page 985 and 986:
STABILITY CHARACTERISTICS 969 drug
Page 987 and 988:
6.2.5 CONCLUSIONS Preformulation te
Page 989 and 990:
REFERENCES 973 16. Huang , L. , and
Page 991:
54. 55. 56. REFERENCES 975 IFAMA (
Page 994 and 995:
978 TABLET DESIGN 6.3.9.3 Case Stud
Page 996 and 997:
980 TABLET DESIGN Another reason, t
Page 998 and 999:
982 TABLET DESIGN E: This ensures t
Page 1000 and 1001:
984 TABLET DESIGN substance would b
Page 1002 and 1003:
986 TABLET DESIGN Plasticity 1.0 0.
Page 1004 and 1005:
988 TABLET DESIGN Drug release (%)
Page 1006 and 1007:
990 TABLET DESIGN FIGURE 9 Dissolut
Page 1008 and 1009:
992 TABLET DESIGN TABLE 2 Number 1
Page 1010 and 1011:
994 TABLET DESIGN Formulation Table
Page 1012 and 1013:
996 TABLET DESIGN TABLE 4 Theophyll
Page 1014 and 1015:
998 TABLET DESIGN often very fi ne,
Page 1016 and 1017:
1000 TABLE 6 Formulations by Wet Gr
Page 1018 and 1019:
1002 TABLET DESIGN 6.3.6.2 FIGURE 1
Page 1020 and 1021:
1004 TABLET DESIGN TABLE 9 Papaveri
Page 1022 and 1023:
1006 TABLET DESIGN TABLE 12 Weight
Page 1024 and 1025:
1008 TABLET DESIGN (3.179 and 4.500
Page 1026 and 1027:
1010 TABLET DESIGN TABLE 14 Run Ord
Page 1028 and 1029:
1012 TABLET DESIGN Regression coeff
Page 1030 and 1031:
1014 TABLET DESIGN to being the out
Page 1032 and 1033:
1016 TABLET DESIGN Mechanical Prope
Page 1034 and 1035:
1018 TABLET DESIGN drawbacks (unsaf
Page 1036 and 1037:
1020 TABLET DESIGN TABLE 16 Basic F
Page 1038 and 1039:
1022 TABLET DESIGN PEG (e.g., Macro
Page 1040 and 1041:
1024 TABLET DESIGN 0.45% 0.40% 0.35
Page 1042 and 1043:
1026 TABLET DESIGN FIGURE 34 Granul
Page 1044 and 1045:
1028 TABLET DESIGN TABLE 19 SEPIFIL
Page 1046 and 1047:
1030 TABLET DESIGN (c) Blistering D
Page 1048 and 1049:
1032 TABLET DESIGN % Dextromethorph
Page 1050 and 1051:
1034 TABLET DESIGN (a) (b) 500 μm
Page 1052 and 1053:
1036 TABLET DESIGN threshold p c1 a
Page 1054 and 1055:
1038 TABLET DESIGN TABLE 24 Composi
Page 1056 and 1057:
1040 TABLET DESIGN Korsmeyer - Pepp
Page 1058 and 1059:
1042 TABLET DESIGN % Water uptake/d
Page 1060 and 1061:
1044 TABLET DESIGN FIGURE 47 Temper
Page 1062 and 1063:
1046 TABLET DESIGN REFERENCES 1. Un
Page 1064 and 1065:
1048 TABLET DESIGN 34. Congreve , M
Page 1066 and 1067:
1050 TABLET DESIGN 73. Miranda , A.
Page 1069 and 1070:
6.4 TABLET PRODUCTION SYSTEMS Katha
Page 1071 and 1072:
PHYSICS OF TABLET FORMATION 1055 en
Page 1073 and 1074:
Tablet production systems can be op
Page 1075 and 1076:
TABLETING MACHINES 1059 Eccentric T
Page 1077 and 1078:
TABLETING MACHINES 1061 In Figure 4
Page 1079 and 1080:
TABLETING MACHINE SIMULATORS (COMPA
Page 1081 and 1082:
TABLETING MACHINE SIMULATORS (COMPA
Page 1083 and 1084:
However, for mechanical compaction
Page 1085 and 1086:
INSTRUMENTATION OF TABLETING MACHIN
Page 1087 and 1088:
Force (kN) FIGURE 13 ANALYSIS OF TA
Page 1089 and 1090:
TABLE 4 Source Emschermann [91] (Fi
Page 1091 and 1092:
TABLE 6 Parameters Directly Deduced
Page 1093 and 1094:
TABLE 7 Parameters Calculated from
Page 1095 and 1096:
ANALYSIS OF TABLETING PROCESS 1079
Page 1097 and 1098:
TABLE 8 Source 3D model [143, 144,
Page 1099 and 1100:
6.4.11 SPECIAL ACCESSORIES OF TABLE
Page 1101 and 1102:
usually tends to vary. However, the
Page 1103 and 1104:
ing at punches and dies. Low produc
Page 1105 and 1106:
REFERENCES 1089 24. Elamin , A. , S
Page 1107 and 1108:
REFERENCES 1091 64. Yeh , C. , Alta
Page 1109 and 1110:
REFERENCES 1093 100. Armstrong , N.
Page 1111 and 1112:
REFERENCES 1095 140. Kuentz , M. ,
Page 1113 and 1114:
REFERENCES 1097 178. Hauschild , K.
Page 1115 and 1116:
6.5 CONTROLLED RELEASE OF DRUGS FRO
Page 1117 and 1118:
INTRODUCTION 1101 ings, and their e
Page 1119 and 1120:
needed to circulate them [57] . Typ
Page 1121 and 1122:
APPLICATIONS 1105 stream. During dr
Page 1123 and 1124:
APPLICATIONS 1107 TABLE 1 Theophyll
Page 1125 and 1126:
APPLICATIONS 1109 FIGURE 1 Release
Page 1127 and 1128:
(a) (b) APPLICATIONS 1111 FIGURE 3
Page 1129 and 1130:
APPLICATIONS 1113 FIGURE 5 Ternary
Page 1131 and 1132:
APPLICATIONS 1115 of the drug, dC/d
Page 1133 and 1134:
APPLICATIONS 1117 FIGURE 9 Ternary
Page 1135 and 1136:
Release rate (mg/min) 0.40 0.30 0.2
Page 1137 and 1138:
REFERENCES REFERENCES 1121 1. Lange
Page 1139 and 1140:
REFERENCES 1123 37. Lin , Y - K. ,
Page 1141 and 1142:
REFERENCES 1125 73. St - Onge , L.
Page 1143 and 1144:
REFERENCES 1127 107. Lai , J. - Y.
Page 1145 and 1146:
APPENDIX 1129 FIGURE A3 Release of
Page 1147 and 1148:
APPENDIX 1131 FIGURE A7 Release of
Page 1149 and 1150:
6.6 TABLET COMPRESSION Helton M. M.
Page 1151 and 1152:
during compression, which will also
Page 1153 and 1154:
of powder mixtures is usually chara
Page 1155 and 1156:
lose in combination with either tal
Page 1157 and 1158:
Due to the signifi cant nonlinearit
Page 1159 and 1160:
EQUIPMENT FOR TABLET COMPRESSION 11
Page 1161 and 1162:
Product Fill cam (mm) column height
Page 1163 and 1164:
TABLET PRESS TOOLING 1147 TABLE 1 T
Page 1165 and 1166:
TABLET PRESS TOOLING 1149 7. Tungst
Page 1167 and 1168:
FIGURE 6 Tooling standards confi gu
Page 1169 and 1170:
6.6.7 TABLE ENGRAVING Engraving is
Page 1171 and 1172:
Shallow and standard concave tablet
Page 1173 and 1174:
is the most popular bisect confi gu
Page 1175 and 1176:
PROBLEMS DURING TABLET MANUFACTURIN
Page 1177 and 1178:
thus reducing a potential variation
Page 1179:
REFERENCES 1163 27. Train , D. ( 19
Page 1182 and 1183:
1166 EFFECTS OF GRINDING IN PHARMAC
Page 1184 and 1185:
Page 1186 and 1187:
Page 1188 and 1189: 1172 EFFECTS OF GRINDING IN PHARMAC
Page 1208 and 1209: 1192 ORAL EXTENDED-RELEASE FORMULAT
Page 1241 and 1242: 7.1 CYCLODEXTRIN - BASED NANOMATERI
Page 1243 and 1244: OH (3) OH (2) HOCH 2 HOCH 2 O O OH
Page 1245 and 1246: APPLICATIONS OF CYCLODEXTRINS IN NA
Page 1247 and 1248: Percentage of release 100 90 80 70
Page 1255 and 1256: O APPLICATIONS OF CYCLODEXTRINS IN
Page 1257 and 1258: β - CDC6 loaded with the model dru
Page 1259 and 1260: REFERENCES 1243 13. Stella , V. J.
Page 1261 and 1262: REFERENCES 1245 49. Dodziuk , H. ,
Page 1263: REFERENCES 1247 81. Memi şo ğlu -
Page 1266 and 1267: 1250 NANOTECHNOLOGY IN PHARMACEUTIC
Page 1288 and 1289:
1272 NANOTECHNOLOGY IN PHARMACEUTIC
Page 1290 and 1291:
Page 1292 and 1293:
Page 1294 and 1295:
Page 1296 and 1297:
Page 1298 and 1299:
Page 1300 and 1301:
Page 1302 and 1303:
Page 1304 and 1305:
Page 1306 and 1307:
1290 PHARMACEUTICAL NANOSYSTEMS 7.3
Page 1308 and 1309:
1292 PHARMACEUTICAL NANOSYSTEMS TAB
Page 1310 and 1311:
Page 1312 and 1313:
1296 PHARMACEUTICAL NANOSYSTEMS Lam
Page 1314 and 1315:
1298 PHARMACEUTICAL NANOSYSTEMS 7.3
Page 1316 and 1317:
1300 PHARMACEUTICAL NANOSYSTEMS sta
Page 1318 and 1319:
Page 1320 and 1321:
1304 PHARMACEUTICAL NANOSYSTEMS har
Page 1322 and 1323:
Page 1324 and 1325:
1308 PHARMACEUTICAL NANOSYSTEMS Sur
Page 1326 and 1327:
1310 PHARMACEUTICAL NANOSYSTEMS Aut
Page 1328 and 1329:
1312 PHARMACEUTICAL NANOSYSTEMS ®
Page 1330 and 1331:
1314 PHARMACEUTICAL NANOSYSTEMS 55.
Page 1332 and 1333:
1316 PHARMACEUTICAL NANOSYSTEMS 100
Page 1334 and 1335:
Page 1336 and 1337:
Page 1338 and 1339:
Page 1340 and 1341:
1324 PHARMACEUTICAL NANOSYSTEMS Nan
Page 1343 and 1344:
7.4 OIL - IN - WATER NANOSIZED EMUL
Page 1345 and 1346:
GENERATIONS OF OIL-IN-WATER NANOSIZ
Page 1347 and 1348:
Page 1349 and 1350:
Page 1351 and 1352:
Page 1353 and 1354:
Page 1355 and 1356:
Page 1357 and 1358:
DRUG-FREE/LOADED OIL-IN-WATER NANOS
Page 1359 and 1360:
EXCIPIENT INCLUSION: OIL-IN-WATER N
Page 1361 and 1362:
EXCIPIENT INCLUSION: OIL-IN-WATER N
Page 1363 and 1364:
MEDICAL APPLICATIONS OF OIL-IN-WATE
Page 1365 and 1366:
Page 1367 and 1368:
Page 1369 and 1370:
Page 1371 and 1372:
evaluation of the lipid hydroperoxi
Page 1373 and 1374:
REFERENCES 1357 21. Ott , G. , Sing
Page 1375 and 1376:
REFERENCES 1359 57. Harris , J. M.
Page 1377 and 1378:
REFERENCES 1361 94. Kim , Y. J. , K
Page 1379 and 1380:
REFERENCES 1363 131. Swietlikowska
Page 1381 and 1382:
REFERENCES 1365 167. Acheampong , A
Page 1383 and 1384:
INDEX Abortifacients, 850 Acyclovir
Page 1385 and 1386:
Lung cancer, 497-502 Lung toxicity,
show all

Pharmaceutical Manufacturing Handbook: Production and

Create successful ePaper yourself

Delete template?

Save as template?